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This supplement is intended to focus on animal models 
of cancer biology. Growing human tumors in nude mice, 
engineering and studying syngeneic animal tumors, 
perspectives on animal models, and large animal endogenous 
tumor models are included within the supplement’s scope.
Cancer Growth and Metastasis aims to provide researchers 
working in this complex, quickly developing field with 
online, open access to scholarly articles on the growth and 
metastasis of cancer. In a field where the literature is ever-
expanding, researchers increasingly need access to up-to-
date, high quality scholarly articles on areas of specific 
contemporary interest. This supplement aims to address 
this by presenting high-quality articles that allow readers 
to distinguish the signal from the noise. The editor in chief 
hopes that through this effort, practitioners and researchers 
will be aided in finding answers to some of the most complex 
and pressing issues of our time.
Articles should focus on animal models of cancer biology 
and may include the following topics:
§§ Growing human tumors in nude mice: methodology, 
advantages, cautions
§§ Engineering and studying syngeneic animal tumors
§§ Perspectives on animal models
§§ Large animal endogenous tumor models.
At the discretion of the guest editors other articles on other 
relevant topics within the scope of the supplement may be 
included.
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Animal models are valuable tools for studying the biol-ogy and genetics of human cancers as well as for pre-clinical investigation of anti-cancer therapeutics and 
cancer prevention. Various animal models have been gener-
ated by genetic engineering, graft transplantation, and viral/
physical/chemical induction. Accumulating data from stud-
ies using those models have enabled us to gain insight into 
the genetic mechanisms underlying malignant transformation 
and cancer progression. Studies from animal models of cancer 
have been utilized for preclinical investigation of therapeutic 
efficacy and toxicity of chemicals and biologicals. Tremen-
dous advances have been made in the generation of animal 
models of cancer, which have become increasingly sophisti-
cated by application of new technologies and integration of 
clinical information from patients. The goals are to faithfully 
recapitulate the human malignant diseases in the animal 
models and apply them as preclinical tools, with the hope of 
successfully translating the basic knowledge into treatment 
and prevention of cancer in humans.
The mouse has been the traditional animal model for 
basic and preclinical studies of cancer, and other organisms 
including zebrafish play important and complimentary roles 
as models of cancer research. Genetically engineered mouse 
and zebrafish models of cancer have been generated by a vari-
ety of interventions such as chemical or physical mutagenesis, 
viral infection, insertion of transgenes, homologous recombi-
nation, and the recently developed gene edition. Studies from 
the genetically engineered models and xenograft models have 
led to discovery of the molecular basis of tumor initiation, 
growth, and metastasis, as well as being utilized for anti-cancer 
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drug discovery and testing. There are numerous publications 
of research studies regarding generation of animal models of 
cancer and their pre-clinical applications. A few recently pub-
lished review articles are cited here for reference.1–5
For this supplementary issue, we invited investigators 
with expertise in various specific areas to contribute  articles 
that focus on cancer biology and genetics using animal 
 models. Several articles focus on mouse models of different 
types of cancer including pancreatic cancer, melanoma, ovar-
ian cancer, esophageal cancer, and skin cancer. Using a mouse 
orthotopic model, Padavano et al applied homologous recom-
bination to disrupt the oncogenic K-RAS in a human pan-
creatic adenocarcinoma cell line and examined cancer growth 
and invasion.6 These data demonstrate that pancreatic cancer 
cells with disrupted mutant K-RAS exhibited reduced tumor 
growth and metastasis, and RhoA and RalA GTPase down-
stream of mutant K-RAS are involved in controlling cancer 
cells migration and invasion. For in vivo studies of melanoma, 
Kuzu et al described a variety of animal models such as geneti-
cally engineered mice, patient-derived tumor xenografts, and 
a topically inducible BRAF mouse model.7 In addition, the 
authors compared the advantages and limitations of these var-
ious models, and discussed how development of those models 
may help improve prediction of investigational drugs for ther-
apeutic efficacy in patients with melanoma. Bobbs et al pro-
vided an overview on the utility of patient-derived xenograft 
and genetically engineered mouse models for recapitulating 
different aspects of ovarian cancer and therapeutic testing.8 
Similarly, Tetreault described tumor xenograft in mice and 
genetically engineered mice for studying esophageal squa-
mous cell carcinoma and adenocarcinoma.9
Several articles in this supplementary issue illustrate 
the utility of animal models for studying other aspects of 
cancer and therapy. In a mouse model of colorectal cancer, 
 LeGendre-McGhee et al conducted a time-serial assessment of 
drug combination interventions using optical coherence tomog-
raphy (OCT).10 They demonstrated the feasibility and valid-
ity of OCT as a minimally invasive modality for monitoring 
tumor development and therapeutic efficacy in mouse models of 
colorectal cancer. Nowotarski et al described mouse models of 
non-melanoma skin cancer induced by chemicals or ultraviolet 
B radiation.11 Based on studies in mice with genetic alteration 
of epidermal polyamines, they discussed the important roles of 
dysregulated polyamines in tumor promotion and the survival 
pathways in epithelia. Animal models of cancer-induced bone 
pain and the mechanistic insights gained from these models are 
being reviewed by Slosky et al.12 They discussed the utility of 
such models to understand the neuromuscular profile of cancer 
pain for the goal of developing effective therapeutics for cancer-
induced bone pain. Finally, the capability of the genetic mouse 
models of cancers to recapitulate human tumors by manipula-
tions of single gene versus multiple genes commonly involved 
in malignancies is reviewed by Lehman and Stairs.13
Animal models of cancer biology are becoming more 
sophisticated by application of new technology, and they play 
ever increasingly important roles in mechanistic studies and 
pre-clinical research. Modeling animals is essential for inves-
tigation of not only tumor growth and metastasis, but also 
tumor-associated inflammation and microenvironment, cancer 
stem cells, tumor heterogeneity, and therapeutic resistance. 
The recently developed CRISPR-Cas9 system for editing the 
genomes of model animals as well as cell lines for animal xeno-
graft models is expected to facilitate recapitulation of human 
malignancies. Animal models, particularly zebrafish, that 
enable high-throughput screening for drug discovery, drug 
validation, and developmental toxicity will play a unique role 
in pre-clinical oncology. Furthermore, application of patient-
derived tumor xenograft in animal models is expected to help 
personalize treatment using chemo- and targeted therapeutics. 
The recently introduced Nonobese  Diabetic Severe Combined 
ImmunoDeficient Gamma (NSG™) mice will provide the 
platforms for patient-derived xenograft to develop immuno-
therapeutics for patients with malignant diseases.
Translating animal models of cancer in combination 
with molecular tumor profiling and developing clinically use-
ful targeted therapeutics are expected to produce a positive 
impact towards the goal of precision treatment that is per-
sonalized for patients with malignant diseases. This supple-
mentary issue, Animal Models of Cancer Biology, is intended 
to provide new insights and updated information on the use 
of animal models for studying different aspects of malignant 
diseases. We hope it will stimulate discussion and collabo-
ration among scientists, clinicians, and health care providers 
for the goal of understanding the mechanisms of malignant 
neoplasia and translating the knowledge into advancement 
of care for patients with cancer. On behalf of the editorial 
office of Cancer Growth and Metastasis, we wish to express our 
sincere gratitude to the reviewers for their time and efforts 
on the manuscripts in this supplementary issue. Their criti-
cal comments are greatly appreciated, and their constructive 
suggestions have helped assure and improve the quality of the 
manuscripts.
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